T. Rowe Price Associates
CRDF icon

T. Rowe Price Associates’s Cardiff Oncology CRDF Stock Holding History

T. Rowe Price Associates’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85K Buy
52,316
+20,986
+67% +$43.1K ﹤0.01% 3028
2025
Q4 		$89K Hold
31,330
– – ﹤0.01% 2963
2025
Q3 		$65K Buy
31,330
+1,187
+4% +$3.28K ﹤0.01% 2985
2025
Q2 		$95K Buy
30,143
+4,984
+20% +$15.2K ﹤0.01% 2903
2025
Q1 		$79K Buy
25,159
+9,769
+63% +$38.6K ﹤0.01% 2869
2024
Q4 		$67K Sell
15,390
-33,847
-69% -$106K ﹤0.01% 2896
2024
Q3 		$132K Hold
49,237
– – ﹤0.01% 2767
2024
Q2 		$110K Buy
49,237
+12,737
+35% +$48K ﹤0.01% 2742
2024
Q1 		$195K Hold
36,500
– – ﹤0.01% 2635
2023
Q4 		$55K Hold
36,500
– – ﹤0.01% 2796
2023
Q3 		$51K Hold
36,500
– – ﹤0.01% 2776
2023
Q2 		$54K Hold
36,500
– – ﹤0.01% 2791
2023
Q1 		$61K Hold
36,500
– – ﹤0.01% 2760
2022
Q4 		$51K Hold
36,500
– – ﹤0.01% 2809
2022
Q3 		$57K Hold
36,500
– – ﹤0.01% 2815
2022
Q2 		$80K Buy
36,500
+15,020
+70% +$25.2K ﹤0.01% 2803
2022
Q1 		$53K Buy
21,480
+800
+4% +$2.83K ﹤0.01% 2918
2021
Q4 		$124K Buy
+20,680
New +$123K ﹤0.01% 2844
2021
Q1 		– Sell
-529,627
Closed -$9.53M – 2847
2020
Q4 		$9.53M Sell
529,627
-23,732
-4% -$417K ﹤0.01% 1355
2020
Q3 		$7.85M Buy
+553,359
New +$3.65M ﹤0.01% 1347
2017
Q2 		– Sell
-246
Closed -$20K – 2561
2017
Q1 		$20K Hold
246
– – ﹤0.01% 2563
2016
Q4 		$37K Sell
246
-1
-0.4% -$234 ﹤0.01% 2537
2016
Q3 		$80K Hold
247
– – ﹤0.01% 2468
2016
Q2 		$81K Buy
+247
New +$85.1K ﹤0.01% 2449

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

T. Rowe Price Associates's CRDF Position: Q1 2026 in Review

T. Rowe Price Associates increased its Cardiff Oncology (CRDF) stake by 67% in Q1 2026, buying an estimated $43.1K and bringing the position to 52,316 shares worth $85K. The position accounts for ﹤0.01% of the portfolio, ranked #3028.

T. Rowe Price Associates first reported a position in CRDF in Q2 2016 and has held it in 24 quarters since. The position peaked at $9.53M in Q4 2020. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • T. Rowe Price Associates held 52,316 shares of Cardiff Oncology worth $85K as of Q1 2026.
  • T. Rowe Price Associates bought 20,986 Cardiff Oncology shares in Q1 2026, an estimated $43.1K.
  • Cardiff Oncology made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #3028 holding.
  • T. Rowe Price Associates first reported a position in Cardiff Oncology in Q2 2016 and has held it in 24 quarters since.
  • T. Rowe Price Associates's Cardiff Oncology position peaked at $9.53M in Q4 2020.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.